Environmental, Social, and Governance (ESG) considerations are increasingly important in the Life Sciences sector’s construction projects, with companies setting themselves ambitious targets.
On the sustainability or environmental piece, the sector is notorious for high energy consumption and emissions profiles. New construction projects are now being designed to reduce environmental footprints through sustainable practices such as energy-efficient facilities, reduced waste, and resource conservation. But can they go further?
Construction projects in the pharmaceutical industry must contend with the sector's distinct complexities, including rigorous contamination prevention measures and the upkeep of specialised facilities required for research, development, and production processes. The implementation of Environmental, Social, and Governance (ESG) strategies in these projects is primarily focused on adhering to regulatory standards, safeguarding the quality of products, protecting the workforce's well-being, and reducing the ecological effects of the construction and operational activities of these new structures.
Linesight convened a panel of experts to discuss these complexities in late 2023.
Some key takeaways from the discussion include:
Share
Related Insights
20 November 2024
Construction Market Insights H2 2024 – Europe
20 November 2024
Construction Market Insights H2 2024 – Americas
20 November 2024
Construction Market Insights H2 2024 – APAC & GCC